Eli Lilly and Company (NYSE:LLY) Shares Down 1.5% After Insider Selling

Key Points

• Eli Lilly shares fell 1.5% after EVP Anat Hakim sold 5,000 shares for approximately $5.95 million under a pre-arranged Rule 10b5-1 trading plan, reducing her holdings by 29.63%.
• Lilly reported strong quarterly results, with revenue up 47.7% year over year to $22.97 billion and EPS of $8.38 versus the $6.40 consensus estimate. Management maintained fiscal 2026 EPS guidance of $35.50 to $36.50.
• Analysts remain broadly bullish, giving the stock a consensus “Moderate Buy” rating and an average price target of $1,292.18, while Lilly’s weight-loss pill Foundayo received U.K. regulatory approval, expanding its obesity-drug portfolio internationally.

Shares of Eli Lilly and Company (NYSE:LLY - Get Free Report) traded down 1.5% during trading on Tuesday following insider selling activity. The stock traded as low as $1,209.53 and last traded at $1,212.9590. Approximately 2,087,326 shares were traded during trading, a decline of 33% from the average session volume of 3,132,333 shares. The stock had previously closed at $1,231.94.

Specifically, EVP Anat Hakim sold 5,000 shares of the company's stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares of the company's stock, valued at approximately $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on LLY. Berenberg Bank raised their price target on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a "hold" rating in a research note on Monday, June 22nd. Bank of America upped their price objective on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a "buy" rating in a research report on Friday, July 10th. The Goldman Sachs Group reiterated a "buy" rating and issued a $1,283.00 target price on shares of Eli Lilly and Company in a research note on Friday, May 22nd. JPMorgan Chase & Co. boosted their target price on shares of Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an "overweight" rating in a research note on Tuesday, July 7th. Finally, Guggenheim raised their price target on shares of Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the stock a "buy" rating in a research note on Monday, July 13th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $1,292.18.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The U.K. Medicines and Healthcare products Regulatory Agency approved Foundayo for weight loss and weight maintenance in certain adults with obesity or overweight-related health conditions. This is the pill’s first regulatory approval outside the United States and gives Lilly access to a major European market. Eli Lilly takes weight-loss pill battle global
• Positive Sentiment: The approval expands Lilly’s obesity portfolio beyond injectable medicines and could improve patient convenience and market adoption. Foundayo will initially be available through private prescriptions, while potential access through Britain’s National Health Service depends on a cost-effectiveness review. Lilly Takes Its Weight-Loss Pill Battle Overseas
• Positive Sentiment: Investor sentiment remains supported by Lilly’s strong recent results: quarterly revenue increased 47.7% year over year to $22.97 billion, while earnings per share of $8.38 exceeded the $6.40 consensus estimate. Management raised fiscal 2026 EPS guidance to $35.50–$36.50, marking another outlook increase. Eli Lilly Beat Big and Raised Guidance
• Neutral Sentiment: Analysts have lifted some valuation targets, with one updated fair-value estimate rising to $1,297.31. However, the stock is trading near its 52-week high and at roughly 41 times earnings, leaving less room for disappointment. Eli Lilly Fair Value Bump
• Negative Sentiment: Erste Group Bank lowered its fiscal 2026 EPS estimate to $34.93 from $35.34. Although the revised forecast remains close to Lilly’s guidance, the cut contrasts with the broader bullish outlook. Eli Lilly analyst estimate
• Negative Sentiment: Executive Vice President Anat Hakim sold 5,000 shares for approximately $5.95 million under a pre-arranged Rule 10b5-1 trading plan. The scheduled nature of the transaction makes it a limited bearish signal, but it may add some selling pressure. SEC Form 4 Filing

Eli Lilly and Company Stock Down 1.5%

The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The company has a fifty day simple moving average of $1,162.38 and a two-hundred day simple moving average of $1,048.95. The firm has a market capitalization of $1.14 trillion, a PE ratio of 40.70, a PEG ratio of 1.38 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating the consensus estimate of $6.40 by $1.98. The firm had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The business's revenue for the quarter was up 47.7% on a year-over-year basis. During the same quarter last year, the firm posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Analysts forecast that Eli Lilly and Company will post 36.77 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company's dividend payout ratio (DPR) is 23.22%.

Institutional Investors Weigh In On Eli Lilly and Company

Several large investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in Eli Lilly and Company by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company's stock worth $88,087,193,000 after buying an additional 1,006,885 shares during the period. BlackRock Inc. raised its position in shares of Eli Lilly and Company by 1.6% in the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company's stock worth $81,009,981,000 after acquiring an additional 1,046,558 shares in the last quarter. State Street Corp raised its position in shares of Eli Lilly and Company by 1.8% in the 4th quarter. State Street Corp now owns 35,361,916 shares of the company's stock worth $38,002,744,000 after acquiring an additional 635,358 shares in the last quarter. Morgan Stanley lifted its stake in shares of Eli Lilly and Company by 2.7% during the 4th quarter. Morgan Stanley now owns 15,593,019 shares of the company's stock worth $16,757,510,000 after purchasing an additional 407,166 shares during the last quarter. Finally, Capital World Investors lifted its stake in shares of Eli Lilly and Company by 0.4% during the 4th quarter. Capital World Investors now owns 15,031,750 shares of the company's stock worth $16,154,619,000 after purchasing an additional 61,851 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source